NEW YORK (GenomeWeb News) – UBS today upgraded Luminex to a Buy rating, noting uptake of the company's gastrointestinal panel, the Eragen acquisition, and a favorable profile amid macro challenges.

The investment bank upgraded the Austin, Texas-based company from a prior Neutral rating and lowered the 12-month price target on its stock to $22 from $25.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.